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Resumo 
Introdução: O Carcinoma de Células Renais (CCR) é o cancro mais letal dos carcinomas urológicos, 
tendo a sua frequência vindo a aumentar nos últimos anos, devido à crescente utilização de 
métodos de imagem. O carcinoma de células claras (ccRCC) é o subtipo histológico mais comum e 
também o que apresenta pior prognóstico, comparativamente aos restantes subtipos histológicos. 
Os biomarcadores epigenéticos tem demonstrado uma crescente importância no âmbito do 
diagnóstico, prognóstico e resposta à terapêutica nos diferentes modelos tumorais. 
Especificamente, a metilação do DNA demonstrou desempenhar um papel fundamental na 
progressão tumoral, podendo também regular outros mecanismos epigenéticos, nomeadamente 
os micro-RNAs (miRNAs). No âmbito dos ccRCCs, o miRNA-30a demonstrou ser particularmente 
relevante, não só como biomarcador diagnóstico, mas também prognóstico, permitindo predizer a 
sobrevida livre de doença. 
Objetivo: Clarificar o papel da metilação do promotor do miRNA-30a como biomarcador em 
ccRCCs, nomeadamente em relação ao seu valor prognóstico. 
Material e Métodos: Foram utilizadas 219 amostras teciduais de ccRCCs, que incluíram ccRCCs 
metastizados e ccRCCs não metastizados, as quais após extração de DNA foram submetidas a 
modificação química por bissulfito. Seguidamente foi realizada a técnica de PCR quantitativo 
específico de metilação em tempo real (qMSP), sendo os níveis de metilação dos genes miRNA-30a 
e ACTβ obtidos e analisados estatisticamente. Para a análise do valor prognóstico, as variáveis 
clinico-patológicas dos respetivos doentes foram recolhidas dos ficheiros clínicos, sendo 
construídas as curvas de sobrevida livre de doença, utilizando o método Kaplan-Meier e o modelo 
de Regressão Cox. 
Resultados: Não foram observadas diferenças nos níveis de metilação do miRNA-30a em doentes 
com ccRCCs que apresentaram metástases ao diagnóstico, comparativamente com os que não 
apresentaram (p=0.324), nem em doentes que recidivaram comparativamente aos doentes que 
não demonstraram recidiva (p=0.325). Contudo, verificou-se uma associação estatisticamente 
significativa entre altos níveis de metilação do miRNA-30a e estadios mais avançados (p=0.031). 
Relativamente ao grau de Fuhrman, não foram observadas diferenças estatísticas nos ccRCCs 
analisados (p=0.505). No que diz respeito à sobrevivência livre de doença, em análise univariável, 
níveis elevados de metilação do miRNA-30a associaram-se a um pior prognóstico (p=0.009); o 
mesmo foi observado para os casos com elevado grau de Fuhrman e estadio patológico (p=0.018 e 
p=0.017, respetivamente). Na análise multivariável, apenas níveis elevados de metilação do miRNA-
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30a e estadios patológicos avançados se associaram com um maior risco de recorrência da doença 
(p=0.030 e p=0.044, respetivamente). Assim, a metilação do miRNA-30a e o estadio patológico 
demonstraram ser variáveis independentes de prognóstico para sobrevida livre de doença nos 
ccRCCs. 
Discussão e Conclusões: Os níveis de metilação do miRNA-30a e o estadio patológico podem ser 
usados como variáveis de prognóstico em ccRCCs, sendo preditores independentes da sobrevida 
livre de doença, o que poderá ser uma ferramenta útil na prática clínica de forma a identificar 
doentes com alto risco de recorrência. Contudo, ao diagnóstico, os níveis de metilação do miRNA-
30a não discriminam doentes com metástases dos sem metástases.  
 
Palavras-chave: microRNA-30a; Metilação do Promotor; Carcinoma de Células Claras Renal; 
Prognostico; Biomarcador; Epigenética  
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Abstract 
Introduction: Renal Cell Carcinomas (RCCs) are the most lethal among urological cancer. Due to the 
widespread use of imaging, the frequency of incidental detection of RCCs has significantly 
increased. The most common RCCs are clear-cell RCC (ccRCC), which have the worse prognosis 
when compared to other histological subtypes. Epigenetic-based biomarkers may assist in 
diagnosis, prognostic stratification and prediction of response to targeted therapy in cancer. 
Specially, DNA methylation has been demonstrated to play a key role in cancer progression and 
could regulate other epigenetic mechanisms, such as micro-RNAs (miRNAs). In the context of 
ccRCCs, miRNA-30a have been demonstrated to have a relevant role, not only as diagnostic 
biomarker but also as prognostic biomarker, predicting disease-free survival. 
Aim: To clarify the role of miRNA-30a promoter methylation in ccRCCs and its prognostic value. 
Materials and Methods: DNA was extracted from a total of 219 tissue samples of ccRCCs, including 
metastatic ccRCCs and non-metastatic ccRCCs. Then, DNA was modified by bisulfite reaction and 
miRNA-30a methylation levels were determined by quantitative real-time Methylation Specific PCR 
(qMSP) and analysed by statistical analysis. The prognostic significance of available clinical variables 
was assessed by constructing disease-free survival, using Kaplan-Meier method and Cox-regression 
model. 
Results: MiRNA-30a methylation levels did not differ significantly between ccRCCs patients that 
presented metastases or relapsed at diagnosis compared with those without metastatic disease or 
recurrence (p = 0.324 and p=0.325, respectively). In our series, a significant association was found 
between miRNA-30a methylation levels and stage (p=0.031), as higher methylation levels of 
miRNA-30a were significantly found in advanced stages (III&IV); however, no statistical significance 
was found for Fuhrman grade (p=0.505). Regarding disease-free survival, in a univariable analysis, 
higher miRNA-30a methylation levels associated with a worse prognosis (p = 0.009); the same was 
observed for cases with high Fuhrman grade and stage (p = 0.018 and p = 0.017, respectively). In 
the multivariable analysis, only high miRNA-30a methylation levels and advanced stages associated 
with a shorter time to relapse (p = 0.030 and p = 0.044, respectively). Thus, miRNA-30a methylation 
and stage are independent prognostic factors for disease-free survival. 
Discussion and Conclusions: MiRNA30a promoter’s methylation levels and stage are independent 
predictors of disease-free survival and may identify ccRCCs patients who are at risk of recurrence. 
However, no differences were apparent concerning miRNA-30a methylation levels in patients 
without metastasis from those harbouring metastases at the diagnosis.  
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1 
Introduction 
Kidney Cancer 
Worldwide, kidney cancer accounts for nearly 2.4% of all adult malignancies, being the 13th 
most common malignancy1. The incidence varies substantially worldwide, with the highest rates 
being generally registered in Europe and North America and the lowest in Asia and South America. 
According to Globocan, in 2012, 337 860 new cases and 143 369 deaths were attributable to kidney 
cancer worldwide, for both sexes1. In the same year, Portugal registered 665 new cases of kidney 
cancer in males and 339 in females, and 240 deaths in men and 128 in women were accounted to 
kidney cancer1. 
Renal Cell Carcinoma 
Renal Cell Carcinoma (RCC) is the most common carcinoma in kidney and it is derived from 
renal tubular epithelial cells. It encompasses a heterogeneous group of cancers with different 
histological subtypes, based on morphological and genetic characteristics2. Three major subtypes 
are recognized, clear-cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC. ccRCC accounts 
approximately 70% to 80% of all RCCs being the most common histological subtype, while the pRCC 
represents 10-15% of RCC, whereas chRCC accounts for 5-7%3. 
Clear-Cell Renal Cell Carcinoma 
ccRCC is the predominant histologic subtype of RCC and it is found in more than 80% of 
patients who develop metastases2. ccRCC arise from the epithelial cells of the proximal tubules3. 
Their causes are not fully understood yet, but specific lifestyle factors have been recognized as 
important etiologic factors for this neoplasia.  
Two of most important risk factors are gender and age, as ccRCCs are more common in 
men, with a male to female predominance of 2:1, and they occur primarily in elderly patients, 
typically within the sixth and seventh decades of life4, 5. Most of ccRCC are sporadic, although 
familiar forms have been reported, as such as von Hippel-Lindau (VHL) syndrome. Many 
environmental factors have been investigated as possible contributing factors in which cigarette 
smoking was identified with a strong association6. 
Concerning macroscopic features, ccRCCs are typically well-circumscribed and lobulated, 
with a yellow cut surface due to the high lipid content of the tumor cells. Microscopically, ccRCC 
has a regular network of small thin-walled blood vessels presenting varied architecture, with solid, 
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alveolar and acinar patterns. CcRCCs primarily metastasize  via the vena cava, to the lung, although 
lymphatic dissemination may also occur3. 
Concerning to genetic changes, chromosome 3 alterations and von Hippel-Lindau Tumor 
Suppressor (VHL) mutations are common in ccRCC; indeed, VHL gene mutation or inactivation by 
hypermethylation was found in the majority (>70%) of ccRCC sporadic cases3, 7.  VHL inactivation is 
thought to be pivotal for ccRCC carcinogenesis. VHL protein targets Hypoxia Inducible Factors (HIFs) 
to ubiquitin-mediated degradation. In the absence of VHL protein, HIFs accumulate and pro-survival 
and pro-angiogenic factors start to be transcribed, as Vascular Endothelial Growth Factors (VEGF) 
and Platelet-derived Growth Factor (PDGF)8-10. 
ccRCCs are most commonly detected as incidentalomas because of the widespread use of 
imaging methods as part of abdominal pain or other unrelated diseases. Consequently, many renal 
tumors are diagnosed at early and less aggressive stages, in which treatment is usually more 
effective. The classic triad of flank pain, hematuria and palpable abdominal mass are nowadays 
rarely found. Other symptoms such as fever, weight loss, anemia and varicocele are also less 
frequent. Because of the retroperitoneal location of the kidney, many renal masses remain 
asymptomatic and no palpable until advanced stages2, 11.  
The current approach for renal masses detection and characterization is based on imaging 
techniques as Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or Ultrasound 
(US)11. Imaging techniques are useful to classify renal masses as solid or cystic and also to classify 
solid masses as benign or malignant, as the presence of enhancement is predictable of malignant 
lesions; CT scan is the most important exam for delineating the nature of renal masses, while MRI 
and US are used when CT scans are indeterminate or there are contraindications for CT use2.  
Staging is based on the American Joint Committee on Cancer (AJCC) Tumor, Node and 
Metastasis (TNM) staging system (Supplementary A 
Table 1) and for RCC there are four stages, varying between stage I and stage IV, according 
to aggressiveness2.  
Concerning treatment, localised disease or advanced disease must be approached 
differently. Currently, depending on tumor size and location, renal function, comorbidities and 
performance status, different strategies for localised ccRCC management are available, including 
nephrectomy, thermal ablative therapies or active surveillance4. Notwithstanding advances in the 
understanding of the genetics and biology of RCC, surgery remains the standard for curative 
treatment11. Because, metastatic ccRCC (ccRCCm) is commonly refractory to chemotherapy and 
surgery has a limited role, different approaches are required. Immunotherapy is one of the options 
to offer to patients with ccRCCm, as interferon alpha (IFN-α) and Interleukin-2 (IL-2) are the most 
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used immune modulators in clinical practice12. Recent advances in molecular biology led to the 
development of novel agents for ccRCCm treatment that block important pathways (angiogenesis, 
cell cycle regulation) in renal carcinogenesis such as VEGF, PDGF and Mammalian Target of 
Rapamycin (mTOR) pathways2, 8, 13. Current challenges include the development of more selective 
drugs targeting these and others undiscovered pathways important for ccRCC carcinogenesis, that 
are actually being developed8, 12, 13. 
Comparing to the other histological subtypes, ccRCC has a worse prognosis, even after 
stratification for stage and grade14. The main prognostic factors used in clinical practice, include 
TNM staging system and pathologic stage as they reflect tumor biology2. In fact, the higher tumor 
stage, associates with worse prognosis, as in stage I >90% of patients is alive in 5-year surveillance, 
whilst patients in stage IV, which has a 5-year surveillance of 1011. Concerning to histological factors, 
Fuhrman nuclear grade system is also an independent prognostic factor with 5-year survival rates 
of 64%, 34%, 31% and 10% for grades 1 to 4, respectively9. Clinical factors such as the Eastern 
Cooperative Oncology Group (ECOG) performance status are also important prognostic factors2. 
 
Epigenetics 
Epigenetics was firstly introduced in 1939 by Waddington, who defined it as “the causal 
interactions between genes and their products, which bring the phenotype into being”; currently 
epigenetics refers to heritable changes in gene expressions that are not due to any alteration in the 
DNA sequence15. It is now acknowledged that epigenetics is implicated in a wide variety of biological 
processes, not only during embryonic development but also during differentiation. A disruption in 
the normal balance of epigenetic marks can result in a deregulation of various signalling pathways, 
and consequently can lead to disease states such as cancer16. 
Currently, three main epigenetic mechanisms are recognized: DNA methylation, post-
translational modifications of histone proteins and chromatin remodelling and non-coding RNAs. 
These three mechanisms, which interact with each other, are dynamic and they work together in 
order to regulate gene expression17. 
DNA Methylation 
DNA methylation is the most extensively studied epigenetic modification in mammals. It 
consists in the addition of a methyl group, by DNA methyltransferases (DNMTs), at the 5’ position 
of a cytosine ring within CpG dinucleotides, mainly found in CpG islands18. CpG islands are 
characterized by a CG content of 50% at least and a ratio of observed/expected CpG dinucleotides 
 
4 
of at least 0.6 17. Moreover, CpG islands are present in about 60% of human gene promoters, which 
makes DNA methylation an important regulatory mechanism of gene transcription19, 20.  
 In normal cells, DNA methylation is implicated in maintenance of genomic imprinting, 
transcriptional regulation, developmental processes and genome integrity. In fact, this alteration 
occurs predominantly in repetitive genomic regions to maintain genomic integrity20. Concerning 
gene expression, CpG islands DNA methylation is generally associated with gene repression and 
with chromatin repressive states. This transcription inhibition occurs directly by blocking the 
binding of specific transcription factors and indirectly by recruitment of methyl-CpG-binding 
domain (MBD) proteins, which in turn recruit histone modifying and chromatin-remodelling 
complexes to methylated sites which ultimately mediate gene repression17, 20. 
Histone Post-Translational Modifications and Chromatin Remodelling 
The nucleosome is the basic unit of chromatin and it is composed of an octamer of histone 
proteins around which 146bp of DNA are wrapped. Histone are small basic proteins containing a 
globular domain, which directly interacts with DNA, and a flexible charged N terminal, also known 
as the histone tail, which protrudes from the nucleosome and can be altered by different post-
translational modifications, such as methylation or acetylation20. The octamer that compose 
nucleosome consists of two subunits of each of the following core histone proteins: H2A, H2B, H3 
and H418.  
Chromatin structure is controlled by two main classes of protein complexes: those that 
remodel nucleosomes in an ATP-dependent manner and those that covalently modify histone tails 
and involve the recruitment of chromatin modulators21. Both determine chromatin status, which 
can be a more condensed pattern, called heterochromatin, which is associated to inactive genes, 
or a more uncondensed configuration, euchromatin, associated to actively transcribed genes18.  
Chromatin remodelling complexes are multi-subunit complexes that use ATP hydrolysis  to 
alter the interaction of DNA and nucleosome and therefore alter the conformation of chromatin; 
these complexes include for example chromatin helicase DNA-binding proteins (CHDs) family22. The 
modulation of chromatin conformation though covalent post-translational modifications (PTMs) of 
histones is another fundamental mechanism of gene transcription regulation and it includes 
methylation, acetylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, or 
deamination23. Histone modifications are thought to alter the electrostatic charge of the histones, 
resulting in a changing in their binding of DNA, which in turn results in different status of 
euchromatin or heterochromatin and consequently in altered transcriptionally activity. The most 
studied and well characterized are histone acetylation and methylation, which are established by 
several enzymes with variable residue-specificity. Whereas histone acetylation occurs at lysine 
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residues and is associated with a more open chromatin conformation and thereby leads to gene 
activation, histone methylation is not so clearly predictable as the consequences on DNA 
transcription depends on the residue affected as well as the degree of methylation (mono, di or 
trimethylation)23. Histone modification levels are predictive of gene expression and recent studies 
have shown that generally, actively transcribed genes are characterized by high levels of 
trimethylation of lysine 4 of histone H3 (H3K4me3) and acetylation of lysine 27 of histone H3 
(H3K27Ac)17, 20. 
MicroRNAs 
MicroRNAs (miRNAs) are a class of non-coding RNAs. Non-coding RNAs are RNAs that do 
not encode for proteins and are regulators of gene expression being described as crucial in several 
cellular pathways24. In fact, they have been implicated in different molecular events in eukaryotic 
cells, including chromosome dynamics, splicing, RNA editing, inhibition of translation and mRNA 
destruction. Non-coding RNAs comprise several different classes, according to their length and their 
function 24. MiRNAs are endogenous single-stranded non-coding RNAs, with 18 to 25 nucleotides in 
length, which are synthesized in the nucleus and then exported to the cytoplasm25. Their effect on 
mRNAs regulation depends on the level of complementarity between miRNA and its target mRNA 
sequence24. Initially, miRNA have been reported as negative regulators of mRNA expression, 
however recent data have indicate an opposite effect, partly explained by binding sites of miRNAs 
in target mRNA26. Each miRNA may regulate multiple mRNAs and, conversely, each mRNA may be 
targeted by multiple miRNAs. In fact, it is estimated that 30 to 70% of human genes are regulated 
by miRNAs, in a temporal and tissue specific manner. Hence, altered miRNAs can dramatically affect 
a variety of cellular processes, namely proliferation, cell death, differentiation and development20, 
24. Although the mechanism underlying miRNA deregulation in cancer is not fully understood, it is 
known that DNA methylation is involved in the regulation of miRNA expression17. New technologies 
have enabled comprehensive analysis of the epigenome and as a consequence, the list of miRNAs 
silenced by methylation in cancer is growing rapidly. Indeed, many families of miRNAs have already 
been described as being silenced by methylation, including the miR-124, miR-34, miR-9, miR-200 
and miR-205 families27.  
Epigenetic Interaction mechanisms: DNA methylation and miRNAs 
Epigenetic mechanisms can interact between each other, reflecting its integrated nature. 
In fact, miRNAs can modulate epigenetic regulatory mechanisms by targeting enzymes responsible 
for DNA methylation, such as DNMT3A and DNMT3B, and histone modifications, as EZH220. 
Specifically, miR-29 family members are downregulated in several cancers and they are predicted 
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to target DNMT1, DNMT3A and DNMT3B. Also, miR-34b has shown to target DNMT1 in prostate 
cancer cell lines, as well as it is also epigenetically silenced by DNA methylation 28. Furthermore in 
ccRCC, DNA promoter methylation levels were inversely correlated with miR-21, miR-10b and miR-
30a expression 29. 
 
Epigenetics and ccRCC 
As in other cancer subtypes, different epigenetic mechanisms have been identified during 
RCC tumorigenesis and progression. In fact, its identification has potential use in molecular 
diagnosis, prognosis and possible therapeutic approaches16. 
Concerning DNA methylation, 70% of sporadic ccRCC cases are characterised by alterations 
on VHL gene, in which 15% of these alterations are caused by  aberrant promoter methylation, 
highlighting the importance of DNA methylation in ccRCC pathogenesis7. Different studies 
comparing DNA methylation profiles between ccRCCs and normal renal tissues has also found 
numerous genes frequently methylation in tumors, including CDH1, APAF1, COL1A1, DKK2, DKK3, 
SFRP1, SFRP4, SFRP5, WIF, PCDH17 and TCF2130. Another CpG methylation study which used 38 
ccRCCs and 9 matched normal kidney tissues identified 55 genes methylated in tumor samples but 
not in normal kidney tissues; these genes included OVOL1, DLEC1, BMP4, SST, TMPRSS2, TM6SF1, 
SLC34A2 and COL1A231. Besides its role in ccRCC tumorigenesis, DNA aberrant methylation is also a 
feasible prognostic tool, reflecting tumor behaviour of ccRCC. In fact, methylation of FAM150A, 
GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCI2, KCNQ1, PRAC, WNT3A, TRH, 
FAM78A, ZNF671, SLC13A5 and NKX6-2 genes were associated with a more aggressive  phenotype 
and a poor outcome30. Moreover APAF1, DAPK132, PTEN33 and JUP34 genes were associated to a 
worse prognosis, even in a multivariate analysis. 
Regarding histone modifications recent data has associated this epigenetic alteration and 
hypoxic cellular response. Indeed, hypoxia was reported to be associated to loss of H3K9Ac, 
increase in H3K9me2 and H3K9me3, typically associated with gene repression, and also with 
increased in H3K14Ac, H3K4me2, H3K4me3 and H3K7me3, associated to gene activation35, 36. 
Several histone marks have also been associated to a poor prognosis including H3K4me2, H3K18ac 
and H3K9me237. Conversely, EZH2 upregulation was associated to a favourable prognosis38. 
Deregulation of miRNA expression was also found in ccRCCs, with diagnostic and prognostic 
value. miR-16, miR18a and miR21 are upregulated in ccRCC and miR-141 and miR-200b are 
described to be downregulated. Nowadays, several pathways were identified as being deregulated 
in ccRCC by miRNAs, which includes metabolism, focal adhesion, cell cycle regulation and 
apoptosis39. Particularly, the miR-200b family is involved in in epithelial to mesenchymal transition 
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and its downregulation might contribute to tumor invasion and metastasis39, 40. For biomarker 
detection, a study demonstrated that a combination of miR-141 and miR-155 was capable of 
distinguish ccRCCs from normal kidney tissue. Concerning to prognosis, miRNA expression could be 
associated to survival or some prognostic factors as overexpression of miR-32, miR-210, miR-21 and 
miR-18a are correlated to poor survival41, 42. Also, higher miR-210 levels were found in tumors with 
higher Fuhrman grade43. Furthermore, lower miR-106b levels were associated with metastatic 
disease44 and high expression levels of miR-210 was correlated to with lymph node metastasis43. 
Micro-RNA 30a Family 
MiRNA-30a belongs to the miRNA-30 family that is codified on chromosome 6q13. This 
family of miRNAs has been implicated  in a widespread of biological processes, including cellular 
differentiation and development45. Indeed, miRNA-30a has been reported to promote 
chondrogenic differentiation via downregulation the expression of Delta-like 4 (DLL4). Moreover, 
miRNA-30 family was found to be regulated by Wnt/ β-catenin pathway45.  
In human cancer, miRNA-30a has been implicated in cellular proliferation, invasion, 
metastasis and autophagy. Specifically in RCC, miRNA-30a was shown to have a critical role in 
autophagy, as it inhibits the autophagy through downregulation of beclin-1, interfering with the 
effectiveness of sorafenib, a multi-kinase inhibitor used in RCC treatment46. Moreover, miRNA-30a 
was significantly downregulated in RCC tissues compared to normal adjacent kidney tissues and in 
RCC cell lines46.  
In a study using microarrays, miRNA-30a was demonstrated to be under-expressed in 
metastatic ccRCCs when compared to non-metastatic ccRCCs. Furthermore, miRNA-30a  lower 
expression were correlated with a worse survival47 and was found to be an independent predictor 
of ccRCC hematogeneous metastases by the univariate analysis48.  
Recently, Wang and colleagues49 not only reported that miRNA-30a was downregulated in 
ccRCCs tissues compared to adjacent normal tissues,  as well as in 5 different RCC cell lines 
compared to a normal kidney cell line, but these authors also found that miRNA-30a low expression 
levels was associated to a high TNM stage and an advanced pathological grade in ccRCC patients. 
In survival analysis, a shorter overall survival time was displayed by these patients compared to RCC 
patients with high miRNA-30a expression 49. 
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Aims of the Study 
 Because miRNA-30a expression levels were found to be deregulated in ccRCCs and miRNA 
expression may be regulated by DNA promoter methylation, the aims of this study are: 
 
I. Assess whether miRNA-30a aberrant promoter methylation might be a metastasis 
biomarker in ccRCCs at the time of diagnosis. 
1. Evaluate the methylation levels of miRNA-30a in metastatic ccRCCs and non-
metastatic ccRCCs; 
2. Correlate methylation levels of miRNA-30a with metastasis and recurrence status; 
3. Correlate methylation levels of miRNA-30a with clinicopathological data (stage and 
Fuhrman grade). 
II. Evaluate the prognostic value of miRNA-30a promoter methylation in ccRCCs. 
4. Correlate methylation levels of miRNA-30a with disease free survival. 
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Materials and Methods 
Patients and Sample Collection 
In the present study, a total of 219 were prospectively collected from patients consecutively 
diagnosed and submitted to nephrectomy at the Portuguese Institute of Oncology – Porto, 
Portugal. All specimens were immediately frozen after surgical procedure and stored at -80ºC for 
further analysis. The presence of tumor cells was confirmed by staining with Haematoxylin and 
Eosin (H&E), before and after the frozen sections were cut, ensuring sampling of more than 70% of 
malignant cells. Relevant clinical data, namely recurrence dates, TNM stage and Fuhrman grade 
was also collected. This study was approved by the Institutional Review Board (CES-IPOFG-EPE 
518/10) of Portuguese Institute of Oncology - Porto, Portugal. 
DNA Extraction 
DNA was extracted by phenol-chloroform method. Briefly, the digestion of tissues was the 
first step, by adding tissue digestion buffer (composed by SE solution - 75mM Sodium Chloride 
[EMD-Millipore and 25 mM EDTA] and 10% of Sodium Dodecyl Sulphate (SDS) [Sigma Aldrich®]) and 
proteinase K (Sigma-Aldrich®), followed by an overnight incubation in a water-bath at 55ºC until 
total digestion was achieved. In some cases, the incubation went for 2 to 3 days and proteinase K 
was added twice a day, until digestion was achieved. Then, phenol/chloroform solution at pH8 
(Sigma Aldrich®) was added in Phase Lock Gel Light  tubes of 2mL (5 Prime, Deutschland, Germany) 
and the upper aqueous phase was collected to a new tube. Then, DNA precipitation was performed 
by adding 100% cold ethanol, 7.5 M ammonium acetate (Sigma-Aldrich®) and 5 mg/mL glycogen 
(Applied Biosystems®), which were mixed and incubated overnight at -20ᴼC. Finally, the samples 
were washed in successive washes with 70% ethanol solution and the pellets were air dried and 
eluted in 30 μL of sterile distilled water (B. Braun, Melsungen, Germany). DNA concentrations were 
determined using a NanoDrop ND-1000 spectrophotometer (Nanodrop Technologies) and stored 
at - 20ºC until used. 
Bisulfite Modification 
After DNA extraction, samples were submitted to a sodium bisulite treatment, which allow the 
identification of methylated and unmethylated cytosines. The basic principle of sodium bisulfite 
modification of DNA is that all unmethylated cytosines are deaminated, sulphonated and then 
converted to thymines, whereas methylated cytosines remain unaltered in the presence of Sodium 
Hydroxide (NaOH) and sodium bisulfite50). Consequently, the sequence of treated DNA will differ 
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depending on whether the DNA is originally methylated or not, since unmethylated cytosines are 
converted to uracil residues and methylated cytosine remain as cytosines. The sodium bisulfite 
modification was performed using EZ DNA Methylation-Gold™ kit (Zymo Research, Orange, CA, 
USA), according manufacturer’s guidelines with 1 μg of DNA in a total volume of 20 μL in sterile 
distilled water used. The denaturation of samples was performed in Veriti® Thermal Cycler, using 
manufacturer’s conditions. CpGenome™ Universal Methylated DNA (EMD-Millipore, Temecula, CA, 
USA) and CpGenome™ Universal Unmethylated DNA (EMD-Millipore) were also modified to be 
used as positive and negative controls of the experiment. Finally, samples were eluted in 60µL of 
sterile distilled water and stored at -80ᴼC, while controls were eluted 30 μL and stored at -20ºC.  
CpG islands were searched in 2000 base pairs upstream of Transcription Start Site (TSS) of 
miRNA30a and a pair of Methylation Specific PCR (MSP) primers were designed by Methyl Primer 
Express® v 1.0. The sequence of MSP primers for miRNA-30a are: Forward 
5’TAGTCGAGGATGTTTATAGTCG3’ and Reverse 5’AACTTCAATACTTTACAAAATCG3’. For ACTβ the 
sequence are: Forward 5’ACCAATAAAACCTACTCCTCCCTTAA3’ and Reverse 
5’TGGTGATGGAGGAGGTTTAGTAAGT3’. 
Quantitative Real-Time Methylation Specific PCR 
To assess methylation levels, quantitative real-time MSP (qMSP) was performed in all 
samples using KAPA SYBR FAST qPCR Kit Master Mix®. The modified DNA was used as template and 
samples were submitted to reactions with the target gene, miR-30a, and the reference gene, ACTβ.  
Reactions were carried out in 384-well plates using LightCycler 480 II (Roche, Germany). 
Briefly, for miRNA-30a, it was added 1 μL of modified DNA, 5 μL of 2X KAPA SYBR FAST qPCR Master 
Mix, 0.3 μL of primer mix and 3.7 μL sterile distilled water in order to total 10 μL of reaction volume, 
per each well; for ACTβ, the volumes for modified DNA and 2X KAPA SYBR FAST qPCR Master Mix 
were the same as miRNA-30a, except to primer mix and sterile distilled water, which were 0.4 μL 
and 5.0 μL, per each well. 
The PCR program consisted of a period of 3 minutes at 95°C for enzyme activation followed 
by 45 cycles with 3 seconds at 95°C (for DNA denaturation) and 30 seconds at 60°C (for annealing, 
extension and data acquisition). 
All samples were run in triplicates and in each plate one negative template control was run. 
Modified CpGenome™ Universal Methylated DNA® was used to create five serial dilutions by a 5x 
dilution factor. These serial dilutions were run in each plate and were used to generate a standard 
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curve thus allowing absolute quantification as well as ascertaining PCR efficiency. All plates had an 
efficiency between 90-100%. 
Methylation levels were calculated as a ratio between the target gene mean quantity and 
ACTβ mean quantity: 
𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙 =
𝑚𝑖𝑅𝑁𝐴 − 30𝑎 𝑚𝑒𝑎𝑛 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦
𝐴𝐶𝑇𝛽 𝑚𝑒𝑎𝑛 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦
 
 
Statystical Analysis 
Non-parametric tests were performed to determine statistical significance in all the 
comparisons made. Kruskal-Wallis test was used in comparisons between 3 or more groups, 
whereas Mann-Whitney U test was used for comparisons between two groups. Qui-Square Test 
was used to seek for differences in the miRNA-30a promoter methylation according to the stage 
categorization and Fuhrman grade. Survival function was performed to evaluate correlation 
between methylation levels and disease specific survival for the 219 ccRCCs patients included in 
this study. The prognostic significance of available clinical variables (metastatic ccRCC or non-
metastatic ccRCC, stage, Fuhrman grade and tumor size) was assessed by constructing disease-free 
survival curves using the Kaplan-Meier method with log-rank test (univariable test). The 
methylation levels of miRNA-30a were classified as low or high based on the cut-off value of 25th 
percentile. A Cox-regression model using ENTER method comprising the different variables 
(multivariable test) was also constructed.  
Statistical analysis was performed using SPSS software for Windows, version 23.0 (IBM-SPSS 
Inc.), and graphs were built using GraphPad Prism 6.0 software for Windows (GraphPad Software 
Inc.). Statistical significance was set at p<0.05.  
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Results 
The relevant clinical and pathological characteristics of patients included in this study 
(n=219) are depicted in Table 2. MiR-30a methylation levels did not significantly differ between 
metastasized patients (n=6) from those patients that did not harbour metastasis at the diagnosis 
(p=0.324) (Figure 1). Furthermore, no significant differences were found between patients who 
relapsed (n=38) and patients who did not relapsed (p=0.325) (Figure 2).  
The distribution of methylation levels of miRNA-30a by stage and Fuhrman grade are 
illustrated in Figure 3 and Figure 4, respectively. In our series, a significant association was found 
between the 25th percentile miRNA-30a methylation levels and stage (p=0.031), as higher 
methylation levels of miRNA-30a (>P25) were significantly found in advanced stages (III&IV) (Figure 
5). No statistically significance was found for Fuhrman grade (p=0.505) (Figure 6). 
For Disease-free survival (DFS) analysis (n=211) 8 patients were excluded, 6 because 
presented metastasis at the diagnosis and other 2 because never presented remission of the 
disease. The median follow-up of ccRCC patients was 61 months (range: 1-195 months). Higher miR-
30a methylation levels significantly associated with poor prognosis (shorter time to recurrence, 
p=0.009) (Figure 7). 
In univariable analysis (Kaplan-Meier), higher stage (≥III) and Fuhrman grade (≥3) associated 
with shorter survival (p=0.017 and p=0.018, respectively) (Figure 8 and Figure 9). Tumor size did not 
disclose any prognostic value within the available follow-up time (p=0.084, data not shown). 
In multivariable analysis (Cox regression), miRNA-30a methylation levels and stage 
predicted shorter disease-free survival. Indeed, a higher recurrence risk was depicted by patients 
with higher stage and higher miR-30a methylation levels (Table 3). 
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Discussion 
Over the last decade, due to the widespread of imaging techniques, the frequency of 
incidental detection of RCCs has significantly increased. ccRCCs are the most common RCCs, which 
have the worse prognosis when compared to other histological subtypes, namely in what concerns 
to the frequency of distant metastasis, which is about 20%14. Indeed, distant metastases are the 
main cause of the high mortality rate of RCCs, making these carcinomas the most lethal among the 
common urologic cancers2. Thus, there is an urgent need of biomarkers capable of accurately 
discriminate tumours that will metastasize from those that will not, especially among those of small 
dimension (mostly pT1). Epigenetic-based biomarkers may assist in diagnosis, prognosis 
stratification and prediction of response to targeted therapy16. In fact, DNA methylation has been 
demonstrated to play an important role in cancer progression by regulating protein coding and 
Non-coding  genes as miRNAs51. In addition, miRNA-30a expression levels demonstrated to be 
deregulated in ccRCC and were reported to convey prognostic significance47-49. In this context we 
assessed whether miRNA-30a methylation levels might be a metastisation biomarker in ccRCCs. To 
achieve that goal, miRNA-30a methylation levels were evaluated in 219 ccRCCs (metastatic ccRCCs 
and non-metastatic ccRCC). Furthermore, the potential significance of miRNA-30a methylation 
levels as prognostic biomarker on disease free survival was also evaluated. 
Herein, miRNA-30a aberrant methylation levels at the diagnosis did not significantly differ 
in patients with metastasis from those patients who did not harbour metastasis. Moreover the 
same occurs for patients who present recurrence during follow up time from those who did not 
relapse. In literature, the studies comparing ccRCCs and miRNA-30a were about expression levels 
and none was conducted using methylation levels of miRNA-30a. In a study led by Heinzelmann and 
colleagues it was demonstrated that miRNA-30a expression levels distinguishes between 
metastatic and non-metastatic ccRCC47, which was not possible to prove in our study. However it is 
important to mention the results published were about a microarray experiment, which used only 
eighteen samples (10 from non-metastatic ccRCCs and 8 from metastatic-ccRCCs) and when these 
results were tried to be validate in a large series, the statistically significance could not be 
demonstrated47. Most of the studies showed a downregulation of miRNA-30a in tumor samples 
when compared to non-tumoral kidney tissues. In fact, this was demonstrated by Huang and 
colleagues which showed a miRNA-30a downregulation in tumor tissues and even a further 
decreased expression levels in hematogenous metastatic ccRCCs, demonstrating that miRNA-30a 
expression levels could be an independent prognostic factor in predicting haematogenic 
metastization48. Wang and colleagues also showed in ccRCCs, a miRNA-30a downregulation in 
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tumors samples when compared to matched normal tissues. Moreover, these results were 
paralleled by renal cell lines studies. The same authors were able to demonstrate that higher 
miRNA-30a expression levels associated with enhanced proliferation in cancer cell lines, whereas 
respective knockdown augmented colony formation and promoted anti-apoptosis, thus suggesting 
an oncogenic activity for this miRNA in RCC49. Moreover, in a recent study, miRNA-30a 
overexpression in 769-P cells prevented cellular proliferation and invasion; and in mice significantly 
decreased tumor volume52. 
Aberrant promoter methylation, globally inversely correlates with miRNA-30a expression 
levels29, we expected that methylation levels significantly differed between metastasized patients 
from those patients without metastasis, nonetheless we were not able to confirm that in our series. 
This might be due to the fact that other mechanisms have been also associated with miRNA-30a 
expression levels regulation, including other molecules involved in autophagy pathways46. 
However, we demonstrated that higher methylation levels are associated with advanced stages, 
which could emphasize the role of promoter methylation on stratifying patients according to 
biological behaviour of ccRCCs. 
Conversely, in disease-free survival analysis, higher miRNA-30a methylation levels 
significantly associated with poor prognosis. Indeed, our results on methylation levels are in line 
with the reported decreased miRNA-30a expression levels in hematogenous metastatic ccRCC. In 
this study by Huang et al, miRNA-30a expression levels were found to be independent predictors of 
ccRCC hematogenous metastasis, along with tumor size. Indeed, the risk of hematogenous 
metastasis in miRNA-30a low-expression levels tumors was 9 fold higher than the tumors 
expressing high miRNA-30a levels48. In accordance with our results, other authors recently reported 
that miRNA-30a downregulation associated with TNM and advanced pathological grade in ccRCCs 
patients. Indeed, Kaplan-Meier survival analysis demonstrated that patients with lower miRNA-30a 
expression had a shorter overall survival time compared ones with high expression levels49. 
Considering that all the above mentioned studies evaluated miRNA-30a expression levels 
in tissue samples and that methylation assessment displays several advantages, including higher 
DNA stability, reduced amount of clinical material and methodological celerity comparing with RNA 
expression assays, methylation analysis would easily applicable to daily clinical practice for non-
invasive testing using either urine or liquid biopsies53, 54. Indeed, it was already showed that miRNA-
30a DNA promoter methylation inversely correlated with respective expression in ccRCCs29, which 
further supports our initial hypothesis. Thus, although the global sample size is relatively high 
(n=219), the number of metastatic ccRCCs is low, with 6 patients, representing 2.7% of our series, 
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thus impacting in the lack of significant association between miRNA-30a methylation levels and the 
risk of developing metastasis in ccRCCs. 
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Conclusions and Future Perspectives 
In this study, although miRNA-30a methylation levels did not significantly differ between 
metastatic ccRCC and non-metastatic ccRCC, higher miRNA-30a methylation levels significantly 
associated with a poor prognosis in these patients. Indeed, stage and higher miRNA-30a 
methylation levels predicted disease-free survival, thus, being useful in predicting the patients at 
higher risk of recurrence and/or metastization.  
As future perspectives, it would be interesting to determine the expression levels of miRNA-
30a in order to conclude whether there was an inversely association with methylation levels in our 
series. Moreover, in vitro studies could also be relevant to determine the expression and 
methylation levels of miRNA-30a in ccRCC cell lines and to understand the pathways involved on its 
regulation such as proliferation, invasion and apoptosis assays. In what concerns to survival we 
intend to assess miRNA-30a methylation levels in a ccRCC series with longer follow-up, to evaluate 
its clinical applicability in predicting metastasis development, and therefore stablish an 
individualized management. Furthermore, it will be also interesting to evaluate the expression and 
methylation levels of other miRNA-30 members, since members such as miRNA-30c were suggested 
to play a potential role in ccRCC tumorigenesis and metastasis development.47  
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Supplementary 
Supplementary A 
Table 1 - TNM Staging System for Renal Cell Carcinoma proposed by the American Joint Committee on Cancer in 2009. 
Stage I tumors are <7cm in greatest diameter and confined to the kidney; stage II tumors are >7cm and confined to the 
kidney; Stage III extend though the renal capsule but are confined to Gerota’s fascia (IIIa) or involve a single hilar lymph 
node (N1); stage IV disease includes tumors that have invaded adjacent organs (excluding adrenal glands) or involve 
multiple lymph nodes or distant metastases. 
T: Primary Tumor 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1  Tumor ≤7.0 cm and confined to the kidney 
T1a Tumor ≤4.0 cm and confined to the kidney 
T1b Tumor >4.0 cm and ≤7.0 cm and confined to the kidney 
T2 Tumor >7.0cm and confined to the kidney 
T2a Tumor >7.0 cm and ≤10.0 cm and confined to the kidney 
T2b Tumor >10.0cm and confined to the kidney 
T3 Tumor extends into major veins or perinephric tissues but not into the ipsilateral 
adrenal gland and not beyond the Gerota fascia 
T3a Tumor grossly extends in the vena cava below the diaphragm 
T3c Tumor grossly extends into the vena cava above the diaphragm or invades the wall of 
the vena cava 
T4 Tumor invades beyond the Gerota fascia (including contiguous extension into the 
ipsilateral adrenal gland) 
N: Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Metastasis in regional lymph node(s) 
M: Distant Metastases 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1  Distant metastasis present 
Stage Grouping 
Stage I T1 N0 M0 
Stage 
II 
T2 N0 M0 
Stage 
III 
T1 or T2 N1 M0 
T3 Any N M0 
Stage 
IV 
T4 Any N M0 
Any T Any N M1 
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Supplementary B 
 
Table 2 - Clinical and Pathological data of patients included in the present study. 
 ccRCC 
Number of Patients, n 219 
Median age, years (range) 64 (29-86) 
Gender, n (%)  
Male 139 (63.5) 
Female 80 (36.5) 
ccRCC, n (%)  
ccRCCm 6 (2.7) 
Non-ccRCCm 213 (97.3) 
Stage, n (%)  
I 113 (51.6) 
II 33 (15.1) 
III 53 (24.2) 
IV 7 (3.2) 
N.A. 13 (5.9) 
Fuhrman Grade, n (%)  
1 6 (2.7) 
2 88 (40.2) 
3 100 (45.7) 
4 24 (11.0) 
N.A. 1 (0.5) 
N.A.: not available  
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Table 3 - Prognostic factors in Disease-free Survival obtained by Cox regression multivariable analysis using Enter method. 
The high and low levels of miRNA-30a methylation levels were categorized using 25th percentile value as cut-off. 
Prognostic Factor Hazard Ratio (HR) 95% CI for HR 
Cox regression p 
value 
miR-30a methylation 
(high vs low levels) 
3.707 1.136 – 12.101 0.030 
Stage 
(high vs low stage) 
1.936 1.019 – 3.680 0.044 
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Figure 1 – Distribution of miRNA-30a methylation levels in clear cell renal 
cell carcinomas (ccRCC) according with metastasis status. 
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Figure 2 - Distribution of miRNA-30a methylation levels in clear cell renal 
cell carcinomas (ccRCC) according with recurrence status. 
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Figure 3 – Distribution of miRNA-30a´s methylation levels by stage. 
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Figure 4 - Distribution of miRNA-30a’s methylation levels by Fuhrman grade. 
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Figure 5 – Distribution of 25th percentile of miRNA-30a methylation levels 
according to low and high stage. The Stage I and II were categorized as Low 
Stage, and Stage III and IV were categorised as High stage. 
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Figure 6 - Distribution of 25th percentile of miRNA-30a methylation levels according to 
low and high Fuhrman grade. The Fuhrman grade 1 and 2 were categorized as Low 
Grade, and Fuhrman grade 3 and 4 were categorised as High grade. 
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Figure 7 - Kaplain Meier estimated disease-free survival curve in 
ccRCCs for miRNA-30a methylation levels categorized using first 
quartil (25th percentile) value as cut-off. 
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Figure 8 - Kaplain Meier estimated disease-free survival curve in ccRCCs for 
stage. The Stage I and II were categorized as Low Stage, and Stage III and 
IV were categorised as High stage. 
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Figure 9 - Kaplain Meier estimated disease-free survival curve in 
ccRCCs for Fuhrman grade. The Fuhrman grade 1 and 2 were 
categorized as Low Grade, and Fuhrman grade 3 and 4 were 
categorised as High grade. 
 
